We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+1.2%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$1.79B
AUM Growth
-$552M
Cap. Flow
+$25.5M
Cap. Flow %
1.42%
Top 10 Hldgs %
44.27%
Holding
146
New
11
Increased
19
Reduced
12
Closed
17

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$32.9M
2
AGEN
Agenus
AGEN
+$27.2M
3
RVMD icon
Revolution Medicines
RVMD
+$21.3M
4
KYMR icon
Kymera Therapeutics
KYMR
+$13.3M
5
VOR icon
Vor Biopharma
VOR
+$11.5M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$53M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$47.9M
3
BLU
BELLUS Health Inc.
BLU
+$21.4M
4
ONC
BeOne Medicines Ltd
ONC
+$9.17M
5
EQRX
EQRx, Inc. Common Stock
EQRX
+$7.88M

Sector Composition

Rank Sector Weight
1 Healthcare 92.03%
2 Consumer Discretionary 3.74%
3 Miscellaneous 3.16%
4 Real Estate 0.39%
5 Financials 0.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XLO icon
101
Xilio Therapeutics
XLO
$59.4M
$1.21M 0.07%
32,143
– –
SQZ
102
DELISTED
SQZ Biotechnologies Company
SQZ
$1.19M 0.07%
1,606,309
– –
MREO
103
Mereo BioPharma
MREO
$45.5M
$1.13M 0.06%
1,500,000
– –
CRDF icon
104
Cardiff Oncology
CRDF
$104M
$1.05M 0.06%
750,000
– –
IGMS
105
CALL
DELISTED
IGM Biosciences
IGMS
$851K 0.05%
50,000
– –
TSLA icon
106
Tesla
TSLA
$1.41T
$776K 0.04%
+6,300
New +$1.19M
KNTE
107
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$763K 0.04%
125,000
– –
INKT icon
108
MiNK Therapeutics
INKT
$58.2M
$756K 0.04%
28,959
– –
TCRR
109
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$749K 0.04%
750,000
– –
HARP
110
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$726K 0.04%
100,000
– –
CRIS icon
111
Curis
CRIS
$2.74M
$715K 0.04%
3,250
– –
LVTX
112
DELISTED
LAVA Therapeutics
LVTX
$700K 0.04%
200,000
– –
ORTX
113
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$669K 0.04%
180,386
– –
CRBU icon
114
Caribou Biosciences
CRBU
$136M
$662K 0.04%
105,347
– –
OLMA icon
115
Olema Pharmaceuticals
OLMA
$856M
$638K 0.04%
260,500
– –
CRVS icon
116
Corvus Pharmaceuticals
CRVS
$1.09B
$425K 0.02%
500,000
– –
MTCR
117
DELISTED
Metacrine, Inc. Common Stock
MTCR
$414K 0.02%
924,898
– –
RUBY
118
DELISTED
Rubius Therapeutics, Inc
RUBY
$357K 0.02%
2,042,666
– –
HIPO icon
119
Hippo Holdings
HIPO
$859M
$326K 0.02%
24,000
– –
APLT
120
DELISTED
Applied Therapeutics
APLT
$304K 0.02%
400,000
– –
NEXI
121
DELISTED
NexImmune, Inc. Common Stock
NEXI
$292K 0.02%
48,000
– –
TIL icon
122
Instil Bio
TIL
$48.9M
$284K 0.02%
22,500
– –
PANW icon
123
Palo Alto Networks
PANW
$307B
$279K 0.02%
+4,000
New +$321K
LITS
124
Lite Strategy Inc
LITS
$37.1M
$244K 0.01%
50,000
– –
KA
125
DELISTED
Kineta, Inc. Common Stock
KA
$197K 0.01%
31,055
-1
-0% -$11
2 3 4
5
6

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q4 2022 Portfolio in Review

As of Q4 2022, Artal Group held 146 positions worth $1.79B, down 24% from $2.34B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Artal Group's Q4 2022 filing shows 11 new, 19 increased, 12 reduced and 17 closed positions. Its largest new stake was Revolution Medicines: 1,000,000 shares worth $23.8M. The largest sale was argenx, an estimated $53M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 78% a quarter earlier, followed by Consumer Discretionary and Miscellaneous.

  • Artal Group's largest Q4 2022 buy was Revolution Medicines: 1,000,000 shares worth $23.8M.
  • Artal Group added most to Mirati Therapeutics, Inc. Common Stock in Q4 2022, an estimated $32.9M increase.
  • Artal Group's biggest Q4 2022 reduction was BELLUS Health Inc., cutting an estimated $21.4M.
  • Artal Group fully exited argenx in Q4 2022, selling an estimated $53M.
  • Artal Group's ten largest holdings make up 44% of its $1.79B portfolio in Q4 2022.
  • Artal Group opened 11 new positions and closed 17 in Q4 2022.
  • Artal Group's portfolio value fell 24% quarter-over-quarter to $1.79B.

Based on Artal Group's 13F filing for Q4 2022, filed 13 Feb 2023.